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Abstract.  Despite the identification and characteriza- 
tion of several distinct ligands for the leukocyte inte- 
grin (CDll/CD18)  family of adhesion receptors, little 
is known about the structural  regions on these mole- 
cules that mediate ligand recognition.  In this report, 
we use ct subunit chimeras of Mac-1  (CDllb/CD18) 
and p150,95 (CDllc/CD18),  and an extended panel of 
newly generated and previously characterized mAbs 
specific to the c~ chain of Mac-1  to map the binding 
sites for four distinct ligands for Mac-l:  iC3b, fibrino- 
gen,  ICAM-1, and the as-yet uncharacterized counter- 
receptor responsible for neutrophil homotypic adhe- 
sion.  Epitopes of mAbs that blocked ligand binding 
were mapped with the chimeras and used to localize 
the ligand recognition sites because the data obtained 
from functional assays with the Mac-1/p150,95 
chimeras were not easily interpreted.  Results show 
that the I domain on the ot chain of Mac-1  is an im- 
portant recognition site for all four ligands,  and that 
the NH2-terminal and perhaps divalent cation binding 
regions but not the COOH-terminal  segment may con- 
tribute.  The recognition sites in the I domain appear 
overlapping but not identical as individual Mac- 
1-1igand  interactions are distinguished by the discrete 
patterns of inhibitory mAbs. Additionally, we find that 
the c~ subunit NH2-terminal region and divalent cation 
binding region, despite being separated by over 200 
amino acids of the I domain,  appear structurally ap- 
posed because three mAbs require the presence of 
both of these regions for antigenic reactivity, and 
chimeras that contain the NH: terminus of p150,95 re- 
quire the divalent cation binding region of p150,95 to 
associate firmly with the/~ subunit. 
T 
HE  leukocyte integrins  comprise  a  group  of three 
closely related cell surface receptors that coordinate 
adhesive interactions  in the immune system (82). The 
members of this subfamily of integrins  (37, 40) are lympho- 
cyte function-associated antigen  (LFA)-I 1 (CDlla/CD18), 
Mac-1  (CDllb/CD18),  and p150,95  (CDllc/CD18).  These 
glycoproteins share a common CD18/~ subunit (95,000 Mr) 
but  have  individual  CDll  st  subunits  (175,000, 160,000, 
150,000  Mr)  that  are  structurally  homologous  (49).  All 
three st subunits share two prominent features in the extracel- 
lular region of the molecule, a putative divalent cation bind- 
ing region consisting  of three tandem repeats of an EF-hand 
motif, and a 200-amino acid inserted or "I" domain (6, 15, 
16, 43, 49, 70). The I domain is absent in all other known 
integrin  st subunits  except for the st1 and st: subunits of the 
VLA subfamily  of integrins  (37, 41). 
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Mac-l, which is expressed primarily on myeloid and natu- 
ral killer cells, has been shown in experiments with blocking 
mAbs to be responsible,  in part, for myeloid cell adhesion 
to and transmigration  across endothelium  (5, 36, 81) or epi- 
thelium  (64),  neutrophil  homotypic adhesion  (4,  66) and 
chemotaxis (4), myeloid cell adhesion to serum coated sub- 
strates  (4,  76),  and the binding  and phagocytosis of op- 
sonized particles (9, 95). These Mac-l-dependent adhesive 
interactions occur through binding to several cell surface and 
soluble ligands including iC3b (9, 60, 95), ICAM-1 (25, 81), 
fibrinogen (35, 97), and factor X (1). p150,95, whose expres- 
sion is restricted to myeloid cells, activated B cells, and some 
T cell subpopulations  is implicated in the adhesion of mono- 
cytes and neutrophils to endothelium and other substrates (4, 
44, 91). While the identity of ligands for p150,95 is less well 
characterized, recent reports suggest that it binds to fibrino- 
gen  (53,  69),  complement (57, 61,  72)~ and at least one 
counter-receptor on the surface of endothelial  cells (86). 
Despite the eDNA cloning and the identification  of an ar- 
ray of ligand  interactions,  the  region(s)  on  the  st  and  /3 
subunits of the leukocyte integrins that mediate ligand bind- 
ing have not been characterized.  The platelet stnb~3 mole- 
cule (CD41/CD61) is the integrin family member that is best 
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ligand recognition. Chemical cross-linking experiments (19) 
and functional studies (20) suggest that fibrinogen binds to 
an  l l-residue  peptide  within  the  divalent  cation  binding 
repeats  on OLnb, and that RGD peptides bind to a site on the 
t3  subunit  between amino  acid  residues  61  and  203  (18, 
80).  A  natural  point  mutation  of residue  119  of the  /33 
subunit  in patients  with Olanzmann's  thrombasthenia  abro- 
gates ligand recognition and disturbs binding of divalent cat- 
ions (52).  However, whether the results  can be generalized 
to the leukocyte integrins is not clear.  Although Mac-1  was 
reported  to  bind  to  RGD-like  sequences  in  some  of its 
ligands (74, 96-98),  recent studies have demonstrated that 
it does  not utilize RGD-like  sequences  to bind  iC3b  and 
fibrinogen (2, 3, 89). Similarly, the binding sites on ICAM-1 
for LFA-1 (88) and Mac-1 (26) do not contain RGD residues. 
Thus far, no data has been reported on the localization of 
ligand binding sites for any of the integrins that contain I do- 
mains.  Because I domains are  structurally  homologous to 
ligand binding modules in von Willebrand factor and com- 
plement factor B (49, 70), it has been speculated that this re- 
gion is involved in the recognition of ligands by leukocyte 
integrins (41, 49, 70). 
We have investigated  the ligand binding regions on the a 
subunit of Mac-1. Mac-1 is one of the most interesting of the 
integrins that contain an I domain as it promiscuously binds 
several  soluble and cell surface ligands.  Because previous 
studies  have  demonstrated  that  distinct  Mac-l-dependent 
adhesive functions are blocked by disparate groups of mAbs 
to Mac-1 ot (4, 22, 24, 95, 97), we hypothesized that separate 
structural domains of the molecule might confer functional 
specificity. Because of the high degree of structural identity, 
antigenic difference, and apparent functional distinction be- 
tween Mac-1  and  p150,95,  we designed  reciprocal  sets  of 
Mac-1/p150,95  chimeras to map structurally  the functional 
domains. We find that the I domain on Mac-1  is critical for 
the recognition of four distinct ligands. 
Materials and Methods 
mAbs 
The following murine mAbs against human antigens were used from as- 
cites: TS1/22 (anti-CDlla, IgG1) (75), LPM19c (anti-CDllb, IgG2a, a gift 
of Dr.  K. Pulford, Oxford,  UK) (92), TMG-65 (anti-CDllb, IgG1,  a gift 
of Dr. I. Ando, Szeged, Hungary) (92), Mn41 (anti-CDllb, IgG1, a gift of 
Dr. J. Buyon, New York)  (30), OKM10 (anti-CDllb, IgG2a, a gift of Dr. 
E  Ran,  Ortho Pharmaceuticals,  Raritan,  NJ)  (95),  VIM12  (anti-CDllb, 
IgG1) (10),  14B6E.2  (anti-CDllb, IgM) and 5A4.C5  (anti-CDllb, IgG1), 
gifts of Dr.  L.  Ashman,  Adelaide,  Australia (92),  CBRplS0/4G1  (anti- 
CDIlc, IgG2a) (86), L29 (anti-CD1 lc, IgG1) (92), BLY6 (anti-CDllc, IgG1) 
(92), and TS1/18 (anti-CDl8, IgOl) (75). The following mAbs were used 
as purified IgG: R15.7 (anti-CDlS, a gift of Dr. R. Rothlein, Boehriager- 
Ingelheim, Ridgefield, CT) (32), OKM1 (anti-CD11b, IgG2a) (95), OKM9 
(anti-CDllb,  IgGl,  a  gift of Dr.  E  Rao,  Ortho  Pharmaceuticals)  (95), 
LM2/1  (anti-CDllb,  IgGl)  (58),  and SHCL3  (anti-CDllc,  IgG2b)  (77). 
M1/87 (anti-Forssman antigen, IgM) (83) was used as a culture supernatant 
after treatment at 60~  for I h. X63 (nonbinding mAb, IgG1) was used as 
culture supernatant. 
Generation of mAbs against human Mac-1 (CBRM1  series) was based 
on a previously published protocol (86). In brief, female BALB/c mice were 
immunized with purified Mac-1 (2/zg/immunization) (25) on day 31  (in- 
traperitoneally) and day 3 (intraperitoneally and intravenously) before fu- 
sion with the nonsecreting murine myeloma P3X63Ag8.653  (CRL  1580; 
American Type Culture Collection, Rockville, MD). Mac-1 was prepared 
for the first immunization by combining 10 #g of purified Mac-1 with treha- 
lose dimycolate from Mycobacterium  phlei, monophosphoryl lipid A from 
Salmonella minnesota R595,  PBS,  1 mM  MgC12,  0.2%  Tween  80,  and 
squaiene  as  described  in  the  manufacturer's  instructions  (RIBI  Im- 
munochem. Ras. Inc., Hamilton, MT). The second immunization was per- 
formed in PBS. Mice were test bled on day 8 before fusion and the titer of 
the antisera by ELISA against purified Mac-1 was 1/5,000.  The protocol for 
fusion and hybridoma maintenance has been described (84). 
Indirect immunofluorescence flow cytometry was used to identify hy- 
bridomas that produced mAbs that bound to peripheral blood nentrophils 
(25). Of the 500 hybridoma supernatants examined ~,20 % contained mAbs 
that recognized antigens on the nentrophil cell surface. These were tested 
subsequently for their ability to bind to peripheral blood lymphocytes and 
to Mac-l- or p150,95-transfected COS or CHO cells to determine whether 
the mAb recognized the a  or/3 chain of Mac-1.24 mAbs were subcloned 
and determined to be specific for the Mac-1 a  subunit, mAbs were isotyped 
using an Immunopure mAb Isotyping Kit (Pierce,  Rockford, IL). 
Generation of  Mac-1/plSO,95 Chimeras 
For production of chimeric Mac-1 and t)150,95  ct chains, oligonucleotide- 
directed mutagenesis (46, 67) was used to introduce restriction sites into 
homologous regions of the eDNA without altering the coding sequence of 
a M (Mac-l)  (16)  and c~  x  (p150,95)  (15)  in pCDM8.  The nucleotide  se- 
quence numbering was according to the published cDNA clones (15,  16). 
Changes were introduced at the following nucleotide sequences to facilitate 
reciprocal  exchanges:  EcoRV  (a  M bp 520-525,  GACATT is changed to 
GATATC; or  x bp 515-520, GACATT is changed to GATATC),  BglII (~x  M bp 
1064-1069,  AGATCT is native; tx  x  bp  1059-1064,  AGATCT is native), 
and AflII (a  M bp  1908-1913,  GCTCAG is changed to CTTAAG;  ct  x  bp 
1900-1905, GCTCAG is changed to CTTAAG). These sites were selected 
to bracket the I domain and divalent cation binding regions based on amino 
acid sequence homology patterns among members of the leukocyte integrin 
family (49).  Genomic cloning of p150,95  (17)  identified the exon-intron 
boundaries that distinguish these regions and confirmed that EcoRV and 
BglII bracket the I domain: the EeoRV site is located 23 nucleotides into 
the first exon (exon 7) of the I domain and the BglII site is 15 nucleotides 
before the end of the last exon (exon 10) of the I domain. The BglII and 
AfllI restriction sites define a region that contains exons 11-13 and the three 
divalent cation binding repeats (exons 14-16): for simplicity this will be re- 
ferred to as the divalent cation binding region: the Bgl II site is 10 nucleo- 
tides before the end of exon 10 and the AflII site is precisely at the end of 
the last exon (exon 16) of the divalent cation binding repeats (17).  Mac-1 
t~ subunits that contained silent mutations were intact antigenicaily and 
functionally as they bound iC3b-E and appropriate tx chain-specific mAbs 
after transfection into COS cells (data not shown). 
For all chimeras,  M  represents a  region of the Mac-1  c~ subunit,  X 
represents a region of the p150,95 c~ subunit, and e, b, and a refer to the 
restriction  sites  EcoRV,  BglII,  and AflH.  M-e-X and X-e-M were  con- 
structed by ligating the EcoRV/NotI fragments of pCDM8-ct M (4.7 kb) or 
pCDM8-c~  x  (4.1  kb) with the NotI/EcoRV  fragments (3.5 or 4.7 kb) of 
pCDM8-w  x  or pCDM8-t~.  M-b-X and X-b-M,  or M-a-X and X-a-M, 
were constructed similarly using the BglII/NotI or the AflIFNotI fragments 
of the  corresponding  plasmids.  M-b-X-a-M  and  X-b-M-a-X  were  con- 
structed by ligating the 0.8-kb BglII/AflII of O/M or tx  x with the AflII/BglII 
fragment of pCDMS-a x (6.7 kb) or pCDMS-tx  M (7.2 kb). M-e-X-b-M was 
constructed by ligating a  SalI/ECORV  (4.5  kb) fragment of pCDMS-a M 
with a BglII/SaiI fragment (3.0 kb) of pCDMS-ct M and a EcoRV/BgllI (0.5- 
kb) fragment of or  x. X-e-M-b-X was constructed by ligating a EcoRV/BgiII 
fragment  (0.5-kb)  of  tx  M with  the  Bgltl/EcoRV  fragment  (7.0  kb)  of 
pCDMS-t~  x. The construction of each chimera was confirmed by restric- 
tion digest analysis, hybridization with appropriate segments of eDNA, and 
by sequencing through the junctions (55). 
Tissue Culture, Transfection, and Cell Preparation 
Neutrophils were isolated from whole blood of healthy volunteers by dex- 
tran sedimentation, Ficoll gradient contdfugation, and hypotonic lysis as 
described (31, 59). Before experimentation, cells were stored at room tem- 
perature in HBSS,  10 mM Hepes pH 7.3,  1 mM MgCl2 in polypropylene 
tubes (Falcon 2097; Becton Dickinson,  Lincoln Park,  NJ). 
COS cells were grown on 15-cm tissue culture-treated plates in RPMI 
1640,  10% FCS (JRH Biosciences, Lenexa, KS) 2 mM glutamine, and 50 
#g/ml gentamicin, and then cotransfected with CsCl-purified ot  M, or  x  or 
chimeric ot  M/x and the common/3 (45) eDNA in pCDM8 by the DEAE- 
dextran method as described (88). Surface expression was monitored 3 d 
after transfection by flow cytometry as described (25). 
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gene were obtained from Dr.  L.  Chasin (Columbia University,  NY) and 
maintained as described (71). Cells were cotransfected  by electroporation 
at 380 V and 960/zF (14) with 25 #g of wild-type or chimeric c~ in pCDMS, 
25 #g of wild-type/~  in pCDM8, and 5 #g of pDCHIP vector that contains 
a CHO dihydrofolate reductase minigene.  Cells were selected as described 
(71) with 0.02 #M methotrexate.  A homogeneous population of positively 
expressing cells was obtained by immunopanning (7). Cells were detached 
with HBSS, 5 mM EDTA, washed three times in c~-MEM, 2.5% dialyzed 
FCS,  incubated with mAb, and panned for 5 rain at room temperature on 
10-cm nontissue culture-treated plates (Lab-Tek 4026; Nunc Inc., Naper- 
ville, IL) that were coated with 50 #g/ml rabbit anti-mouse IgG (Zymed 
Laboratories, San Francisco,  CA).  Nonadherent cells were  removed  by 
eight changes of media, and adherent cells were recovered after treatment 
with trypsin-EDTA.  Cells were cultured and repanned several days later. 
Expression was augmented by increasing the concentration of methotrexate 
(0.05-0.20  #M) in culture.  As controls, CHO cells expressing  a domain- 
deleted form of ICAM-1 (domain 3 deleted, F185) (87) were generated by 
cotransfection of the F185 eDNA in pCDM8 with pDCHIP followed by se- 
lection and immunopanning as described. For all transfectants,  surface ex- 
pression was monitored by immunofluorescent  flow cytometry. 
The ICAM-1  + L cell stable transfectants  were maintained on 15-cm tis- 
sue culture plates in DME, 10 % heat-inactivated FCS (low endotoxin serum 
[defined]; Hyclone Labs., Logan, UT), 2 mM glutamine, and 50 ~g/ml gen- 
tamicin as previously described (25). Before adhesion assays, cells were re- 
moved from tissue culture plates with trypsin-EDTA,  and washed twice in 
PBS, 2 mM MgC12, 0.5%  heat-treated  BSA (25). 
Surface Labeling, lmmunoprecipitation, 
and Gel Electrophoresis 
Transfected  COS  or  CHO  cells  (1-2  x  106 cells) were detached with 
HBSS, 5 mM EDTA, washed four times with PBS, and resuspended in 2 
nil. The Cells were iodinated, lysed, and precleared as described (26). Im- 
munnprecipitations were performed as follows: Immune complexes  were 
formed by incubating mAb (250 pl vol of neat supematant, 1:100 dilution 
of ascites, 25 #g/mi purified mAb) with purified rabbit anti-mouse antibody 
(5/zl of 1 mg/ml, Zymed Laboratories) for 4 h at 4~  Protein A-Sepharose 
(Pharmacia LKB, Piscataway, NJ) (25 #1 of a 1:1 slurry) was added for over- 
night incubation. Eppendorf tubes were centrifuged,  supematants were 
aspirated, and iodinated lysate (50/zl) was added and incubated for 2 h at 
4~  while  shaking  vigorously.  The  washing  and  elution  of  the  im- 
munoprecipitates have been described (26). Samples were loaded and sub- 
jected to SDS-PAGE (47) in the presence of 5 %/~-mercaptocthannl  and au- 
toradiographed (50). 
iC3b-E Preparation and Binding Assay 
IgM- and iC3b-coated erythrocytes (IgM-E, iC3b-E) were prepared as de- 
scribed previously (73) with the following modifications.  In some experi- 
ments, sheep erythrocytes (Colorado Serum Co., Denver, CO) were washed 
once in PBS, and fluoresceinated  for 2 h at 37~  with a 0.22-/~m filtered 
solution of FITC (0.8 mg/ml in PBS after being dissolved in 30 #I DMSO). 
Erythrocytes were washed three times in HBSS,  10 mM Hepes,  pH 7.3, 2 
mM MgC12, resuspended  (6  x  l0  s cells in 10 ml), and incubated with a 
1:128 dilution of heat-inactivated  anti-Forssman IgM mAb (M1/87) for 60 
rain at room temperature while shaking gently.  IgM-coated erythrocytes 
(IgM-E) were washed three times, resuspended (1 ml) in HBSS,  10 mM 
Hepes,  1 mM MgCl2,  1 mM CaC12 supplemented with C5-deficient  hu- 
man serum (100 ~1) (Sigma Chem. Co., St. Louis, MO), and incubated for 
60 rain at 37~  while rotating. IC3b-E and IgM-E were washed three times 
and resuspended (4 ￿  107 ceUs/ml) in HBSS,  1 mM MgCI2, 1 mM CaCl2, 
10 mM Hepes,  pH 7.3. 
Neutrophils and transfected CHO cells were assayed for binding to iC3b- 
E.  Peripheral blood neutrophils (1.25  x  105 cells/well  in 50 #1)  were 
seeded onto 96-well tissue culture-treated plates (Coming Glass Inc., Com- 
ing, NY) in HBSS,  10 mM Hepes,  pH 7.3, 1 mM MgCI2, 1 mM CaCI2 for 
20 min at 37~  in a 5% CO2 incubator; nonadherent cells were removed 
after two washes  with the same buffer.  Adherent neutrophils were prein- 
cubated with mAb (addition of 50/~1 of diluted ascites or purified mAb in 
PBS,  1 mM MgC12, 0.5% BSA) for 20 rain; each condition was performed 
in quintuplicate.  Subsequently, iC3b- or IgM-sensitized  fluorescein-labeled 
erythrocytes (2  x  106 in 50 ~1) and PMA (65 ng/ml final concentration) 
were  added; the  erythrocytes  were centrifuged  (300 rpm, 5 rain, 4~  onto 
the neutrophils  and the plates  were incubated  in a 37~  water bath for 15 
rain.  Nonadherent erythrocytes  were removed  by flicking  the plates six 
times after addition of PBS, 1 mM MgCI2, 0.5 % BSA (175 ~l/weU). Bound 
erythrocytes were qnantitated in the 96-well plates using a Pandex fluores- 
cence concentration analyzer (Baxter Healthcare Corp., Mundelein, IL). 
The percentage of inhibition was normalized as follows: 
(% iC3b-E binding without mAb 
% Inhibition =  100  ￿  -  % iC3b-E binding with mAb) 
(% iC3b-E binding without mAb) 
Transfected  CHO cells (2  ￿  105 cells/nil in 250 #1) were seeded  onto 
6-well tissue culture-treated plates in L15, 10 mM Hepes, pH 7.3, 5% heat- 
inactivated FCS and adhered for >3 h at 37~  Subsequently,  iC3b-E or 
IgM-E (2 ￿  10a/ml, 50/tl) and PMA (100 ng/ml final concentration) were 
added and cells were bound for 60 rain at 37~  Nonadherent erythrocytes 
were removed after six to eight washes and rosettes (>10 erythrocytes/CHO 
cell,  >100  cells examined)  were  scored  by light microscopy  at 200￿ 
magnification. 
Neutrophil Homotypic Adhesion Assays 
Previously, two methods have been utilized to qnantitate  neutrophll aggrega- 
tion: microscopic determination of the number of free neutrophils (those 
not found in cell conjugates) (24, 65) or aggregometry, which measures the 
increase in light transmission that occurs when cells form clusters (4, 12, 
35).  While both methods are reproducible,  the former is labor intensive, 
and the latter indirectly  measures the number and size of cell aggregates. 
We devised an alternate method which uses a Coulter counter; it is auto- 
mated, reproducible,  and scores mechanically the total number of cell parti- 
cles in a fixed volume.  Since the Coulter counter treats cell aggregates, 
regardless  of size, as single particles, small numbers of two- or three-cell 
aggregates  significantly  affect the particle count.  Neutrophils (2  x  107 
cells/ml) were resuspended in HBSS, 10 mM Hepes,  1 mM MgC12, 1 mM 
CaC12, 0.5%  HSA  (HHMCH) 0.325-mi  aliquots  were preincubated with 
mAb (1:200 dilution of ascites, 20/~g/mi purified mAb) for 25 rain at room 
temperature. These cells (0.3 rni) were then added to a prewet polypropyl- 
ene eppendorf tube (1.5 mi) that contained 0.1 mi of HHMCH. PMA was 
added (100 ng/mi final concentration) and the tubes were rocked gently on 
their sides for 15 rain at 37~  on a Bollco Rocker Platform (Bellco Biotech- 
nology, Vineland, NJ).  Subsequently,  0.2-mi aliquot was transferred to a 
conical tube (3 mi, Sarstedt Inc., Germany) that contained HBSS,  10 mM 
Hepes,  2% paraformaldehyde  (0.1 mi), and the number of particles (single 
cells or cell aggregates)  in a fixed volume was determined with a Model 
S-Plus counter (Coulter Corp., Hialeah, FL). The average of two readings 
was used as an individual datapoint. Each condition was repeated at least 
three times with different donors.  The percent aggregation  was determined 
according to the following equation: 
(n particles in a sample stimulated  ~ 
with PMA) 
%  Aggregation  -- 100  ￿  1 -  (~  i~~  .) 
The percent inhibition  was determined according to the following equation: 
(% aggregation  with PMA  - 
%  Inhibition  -- 100 x  %  aggregation  mAb  +  PMA) 
(% aggregation  with PMA) 
Neutrophil aggregometry was performed as described  (35).  0.5-ml ali- 
quots of ncutrophils  (107  cells/ml)  were preincubated with mAbs for at 
least 25 rain at room temperature.  0.4 mi aliquots of neutrophils were stirred 
(700 rpm) at 37~  in a siliconized cuvette in a standard platelet aggregome- 
ter (model DP-247F; Sienco Inc., Morrison, CO). A baseline was recorded 
for 3 rain at which time PMA (100 ng/mi) was added and the change in light 
transmission was monitored on a strip chart recorder. 
Adhesion of  Neutrophils to Purified Fibrinogen 
Purified  fibrinogan (Sigma  Chem.  Co.)  was  resuspended in PBS  (2.0 
mg/ml) and spotted (25 #1) onto 6-cm bacterial petri dishes (Falcon 1007; 
Becton Dickinson) for 90 rain at room temperature. Plates were blocked 
with the detergent Tween 20 as described (26). Neutrophlls (4 x  106 cells 
in 1 ml) were resuspended in HBSS,  10 mM Hepes, pH 7.3, 1 rnM MgCI2 
and preincubated with mAbs for 25 rain at room temperature.  Subsequently, 
cells were added to the dishes in the presence or absence of formyl-methio- 
nine-leucine-phenylalanine  (fMLP) (10  -7 M, final volume of 3 ml), and al- 
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12 washes with a Pasteur pipette after gentle swirling with the same buffer 
supplemented with 0.5 % BSA. Binding was quantitated by scoring the num- 
ber of adherent cells in at least four different fields using an ocular grid at 
100￿  magnification.  The percent inhibition  by raAb was determined upon 
comparison with the media control. 
Binding of ICAM-1  +  L Cells to Purified Mac-1 
The binding of ICAM-I+L cells to Mac-1 is a modification  of previously 
described protocol (25). Briefly, Mac-I that was purified from leukocyte ly- 
sates as described was diluted, adsorbed (30/~1) to 6-era petri dishes, and 
blocked with 0.5% heat-treated BSA as described (25).  30 rain before the 
binding assay, the plates were preincubated at room temperature with mAb 
(1:200 dilution of ascites or 20/~g/ml of purified mAb) in PBS,  2  mM 
MgCl2, 0.5% heat-treated BSA (PMBSA, 2 ml). ICAM-I+L cells were re- 
moved  from  tissue  culture  plates  with  trypsin-EDTA  (GIBCO  BRL, 
Gaithersburg, MD), washed twice, and resuspended in PMBSA (0.5-1.0  ￿ 
106 cells/ml).  Some aliquots were preincubated for 25 rain at room temper- 
ature with control or anti-ICAM-1 mAbs. The binding assay was performed 
as described (26).  The percent inhibition by mAb was determined upon 
comparison with the media control. 
Binding of CHO Cell Chimeras to Purified ICAM-1 
The binding of transfeeted CHO ceils to ICAMA is a modification of a pre- 
viously described protocol for COS cell transfectants  (25). Briefly, ICAM-1 
that was  purified  from  the  erythroleukemic cell  line K562  by  RR1/1- 
Sepharose irnmunoaflinity chromatography (56) was diluted and adsorbed 
(25 ~1) to 6-cm petri dishes. After a 90-rain incubation, nonspecific binding 
sites were blocked with 0.5% heat-a'eated BSA. CHO cell transfeetants, af- 
ter removal from tissue culture plates with HBSS,  10 mM Hepes, pH 7.3, 
5 mM EDTA,  were washed twice and resuspended (8  x  105 cells/ml) in 
HBSS,  10 mM Hepes, pH 7.3, 1 mM MgC12, 0.5% hot-treated BSA, and 
bound to ICAM-l-coated Patti dishes for 90 rain at room temperature. 
Nonadherent cells were removed after five washes with a Pasteur pipette 
and the number of adherent cells was determined by light microscopy  at 
100x using an ocular grid. 
Results 
Generation and Expression of  Mac-I/plSO,95 Chimeras 
Naturally occurring restriction sites and sites introduced by 
silent mutations were used to divide the Mac-1 and p150,95 
ot subunits into four structurally discrete regions (Fig.  1). 
COS  cells  transiently  transfected  with  the  chimeric  ot 
subunits and the common CD18 ~ subunit were subjected to 
immunofluorescence flow cytometry and immunoprecipita- 
tion with a panel of previously characterized mAbs to the c~ 
subunits of Mac-1 and 1)150,95. Most of the chimeras were 
expressed on the cell surface and were stained with a unique 
pattern of mAbs to Mac-1  and i)150,95 (Table I). The data 
obtained by immunofluorescence was confirmed by immu- 
noprecipitation and showed that most of the  chimeric  ot 
subunits associated stably with the/3 subunit (Fig. 2, and 
data not shown). However, not all of the chimeras were ex- 
pressed properly in COS cells: two (X-b-M and X-b-M-a-X) 
were synthesized in a form that did not associate with the/3 
subunit and were retained in the cell (data not shown), and 
a third (X-e-M) which showed moderate cell surface expres- 
sion had an abnormal pattern of immunoprecipitation, as 
mAbs to the ot subunit precipitated only the c~ chain, and 
mAbs to the/3 subunit precipitated neither the a nor ~ chains 
(data not shown). 
Since a subset of  chimeras was not expressed in COS cells, 
stable expression in CHO cells was used to map definitively 
the structural epitopes of mAbs and to perform functional 
analyses. Chimeric oe and wild-type 8  subunits were co- 
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E~RV 
I! 
M-e-X 
X-e-M 
M-b-X 
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X-b-M 
M-a-X 
X-a-M 
M-e-X-b-M 
X-e-M-b-X 
IIIilll  Aflll 
M-b-X-a-M 
X-b-M-a-X 
Figure 1. Schematic  representation of  the leukocyte  integrin t~ chain 
and Mac-1/p150,95 chimeras. Restriction  sites (e, EcoRV; b, BgllI; 
a, ArID that facilitated reciprocal exchanges  are indicated with ar- 
rows or in the name of each chimera. 
transfected with the pDCHIP plasmid into CHO DG 44 cells 
(71) that lack functional dihydrofolate reductase. After drug 
and antibody selection, flow cytometric analyses confirmed 
that all of the chimeric molecules were expressed on the 
surface of CHO cells and the levels of the tx and/3 chains 
were equivalent for each chimera (Fig. 3). In one case (M-b- 
X-a-M), the level of ~ subunit on the surface exceeded the 
level of t~ subunit (Fig. 3). Despite expressing all molecules 
on the cell surface, immunoprecipitation studies revealed an 
aberrant association between the o~ and ~ subunits in three 
of the  chimeras.  Immunoprecipitation of surface-labeled 
X-e-M, X-b-M, and X-b-M-a-X chimeras with the/~ subunit 
mAb (TSlfI8) were either weak or absent (Fig. 4, B, E, and 
J; lanes 3). These three chimeras apparently lost the TSlfI8 
epitope on the/3 subunit after detergent solubilization. Previ- 
ously we have shown that TS1/18 immunoprecipitates LFA-1, 
Mac-l, and t)150,95 or/3 complexes but not the unassociated 
c~ and :l subunits (29, 85). Despite the loss of the TS1/18 epi- 
tope, the/~ subunit remained partially associated with these 
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mAb  M-e-X  X-e-M  M-b-X  X-b-M  M-a-X  X-a-M  M-e-X-b-M  X-e-M-b-X  M-b-X-a-M  X-b-M-a-X 
Mac  - 1 
LPM19c  -  +  +  -  +  -  -  + 
14B6E.2  -  +  +  -  +  -  -  + 
5A4.C5  -  +  +  -  +  -  -  + 
Mn41  -  +  +  -  +  -  -  + 
TMG65  -  +  +  -  +  -  -  + 
VIM12  -  +  -  -  -  +  +  - 
LM2/1  -  +  +  -  +  -  -  + 
OKM1  -  +  -  -  -  +  +  - 
OKM9  -  +  +  -  +  -  -  + 
OKM10  ....  +  -  +  - 
p150,95 
SHCL3  .....  +  -  + 
L29  +  -  +  -  +  -  -  - 
BLY6  +  ....  +  +  - 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Summary of mAb  reactivity as  determined by  immunofluorescent flow cytometry on  COS  cells transfected with wild-type or  chimeric Mac-1  and p150,95 
molecules. (+) Positive staining; (-)  staining was not significantly different from the negative control (X63); and (+) staining was marginally greater than the 
negative control. 
Figure 2.  SDS-PAGE of Mac- 
1,  p150,95,  or  Mac-1/p150,95 
chimeras immunoprecipitated 
from  1~5I-COS  cell  detergent 
lysates.  COS  ceils  were  co- 
transfected  with  the  13  sub- 
unit and (A) Mac-l, (B) p150,95, 
(C)  M-e-X-b-M,  or  (D)  X-e- 
M-b-X cDNA,  surface labeled 
with 125I,  and immunoprecip- 
itated with X63 (lanes 1, nega- 
tive control),  TS1/18  (lanes 2, 
anti-CD18),  LM2/1  (lanes  3, 
anti-CDllb),  Mn41  (lanes  4, 
anti-CDllb),  VIM12  (lanes 5, 
anti-CDllb),  OKM1  (lanes 6, 
anti-CDllb),  OKM10otd  (lanes 
7,  anti-CD1  lb),  SHCL3  (lanes 
8,  anti-CDllc),  BLY6  (lanes 
9, anti-CDllc), and L29 (lanes 
10,  anti-CDllc)  as  described 
in  Materials  and  Methods. 
Material  was  boiled  in  SDS 
sample buffer with 5 %/3-mer- 
captoethanol,  electrophoresed 
on a  7 %  polyacrylamide  gel, 
and  autoradiographed.  Mo- 
lecular weights of the protein 
standards are  indicated in the 
center. 
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Figure 3. Flow cytometry  profiles of CHO cells expressing Mac-l, 
p150,95 and Mae-1/p150,95 chimeras. CHO cell transfeetants (indi- 
cated on right) were immunostained with either a negative control 
(X63), a mAb to the I domain (LM2/1) or COOH-terminal (OKM1) 
region of  the Mac-1 c~ subunit, a mAb to the COOH-terminal region 
of the p150,95 ,~ subunit (CBRpl50/4G1), or a mAb to the CD18 
/3 subunit (TS1/18). Ceils were subjected to immunofluorescent  flow 
cytometry. Each histogram shows the negative control (X63, light 
line) and the mAb indicated at the top of the eolunm (dark line). 
chimeric o~ subunits; it was coprecipitated by the c~ subunit- 
specific mAbs but in a lower stoichiometric ratio to the/3 
subunit than for other chimeras (Fig. 4 B, E, and J; lanes 2). 
Epitope Mapping of mAbs to Mac-1 
Because an improper association of c~ and/3 subunits in a 
subset of chimeras could affect functional assays and our 
subsequent analyses,  we used mAbs  to generate a  struc- 
ture-function map of the ligand binding domains on Mac-1. 
mAb epitopes were localized on the Mac-1 ~ subunit by their 
ability to bind to a particular subset of chimeras and the 
results correlated with the ability of the mAb to block dis- 
tinct adhesive functions of the native Mac-1  molecule. To 
supplement the 10 mAbs that had been previously character- 
ized, 24 new mAbs against the c~ chain of Mac-1 were gener- 
ated  (Fig.  5)  by  immunization  with  purified Mac-1  and 
screening by immunofluorescent flow cytometry on neutro- 
phils, lymphocytes, and transfected cells. 
To map the structural epitopes of the 34 mAbs against the 
Mac-1 ot subunit, the CHO cells expressing wild-type and 
chimeric Mac-1 and p150,95 were tested for their differential 
ability to bind mAbs (Fig, 5).  Of the 34 mAbs examined, 
19 localized to the I domain,  11 to the COOH-terminal re- 
gion, and one (CBRM1/20) to the region containing the diva- 
lent  cation binding  repeats.  Two mAbs  (CBRM1/32  and 
OKM10o~a) localized  to  a  discontinuous  epitope  that  re- 
quired the presence of both the NH2-terminal and divalent 
cation binding  regions.  (The OKM10~w that we  received 
from Ortho Pharmaceuticals is distinct from the OKM10o~d. 
The new OKM10 does not block iC3b-E binding to Mac-1 
as  was  described  [4,  95]  and  as  we  have  verified  for 
OKM10o~d, and the two mAbs do not localize to the same 
region of Mac-1  [Fig. 5].) We were unable to localize the 
structural epitope of two mAbs  (OKM10~w  and CBRM1/ 
28).  Three mAbs against the p150,95  o~ subunit also were 
mapped with the CHO cell chimeras: CBRpl50/4G1 mapped 
to the COOH-terminal region, BLY6 localized to the I do- 
main,  and  SHCL3  mapped  to  sites  both  in  the  NH2- 
terminal and divalent cation binding regions. 
Inhibitory Activity of mAbs 
iC3b-E Binding to Mac-1. The ability to inhibit individual 
Mac-l-dependent adhesive functions was investigated with 
the extended panel of mAbs. To test which mAbs block iC3b 
binding  to  Mac-l,  a  quantitative  assay  was  developed in 
which FITC-labeled iC3b erythrocytes were incubated with 
adherent neutrophils in the presence of mAbs to Mac-1 (Fig. 
6). mAbs to the I domain inhibited iC3b-E binding to neu- 
trophils with a mean of 72.6 +  24.9%, whereas mAbs to the 
COOH-terminal  region  blocked with  a  mean  of 33.6  + 
16.6%. 11 of 19 mAbs that mapped to the I domain blocked 
strongly  (>85%),  whereas  no  mAb  that  localized to  the 
COOH-terminal region showed >60%  inhibition. The one 
mAb  (CBRM1/20)  which mapped directly to the divalent 
cation binding region had little inhibitory effect. The two 
mAbs (OKMi0old and CBRM1/32) that mapped to sites in 
both the NH~-terminal and divalent cation regions blocked 
81 and 65% of the binding (Fig. 6). 
Neutrophil Homotypic Adhesion.  Several groups have 
demonstrated that activated neutrophils bind homotypically, 
and that this aggregation response is blocked by mAbs to the 
o~ or/3 chains of Mac-1 (4, 8, 12, 65). The ligand on neutro- 
phils  for Mac-1  that mediates homotypic aggregation re- 
mains uncharacterized. To determine the regions of Mac-1 
that were important for neutrophil homotypic adhesion, we 
tested the panel of mAbs for their ability to inhibit this inter- 
action  in  a  newly  developed Coulter  counter assay  (see 
Materials and Methods). This assay, which counts the num- 
ber  of particles,  is  more  stringent than  the  classical  ag- 
gregometry assay; mAbs that inhibit in this assay by 20-30% 
such as CBM1/2 and Mn41 (Fig. 6) show 56 and 67 % inhibi- 
tion  in  the  light  scattering  aggregometry assay  (Fig.  7). 
mAbs to the I domain blocked the aggregation assays with 
a  mean of 25.9  5:  16.1%,  whereas mAbs  to the COOH- 
terminal region blocked with a mean of 1.8  +  1.1%. Two 
mAbs (LPM19c and CBRM1/29) to the I  domain blocked 
neutrophil homotypic adhesion in the Coulter counter assay 
strongly by 81 and 51%. The CBRM1/32 mAb to the NH2- 
terminal and divalent cation binding regions blocked 21%, 
and the CBRM1/20 mAb to the divalent cation binding re- 
gion inhibited 7 %. 
Neutrophil Adhesion to Purified Fibrinogen. When neu- 
trophils are  stimulated with  fMLP (10  -7  M)  they bind to 
fibrinogen in an almost exclusively Mac-l-dependent man- 
ner.  mAbs to the I  domain of Mac-1  inhibited binding to 
fibrinogen  strongly  (Fig.  6)  with  an  average  of 77.6  + 
13.2%,  whereas  mAbs  to the COOH-terminal  region re- 
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1, p150,95, or Mac-1/p150,95 
chimera  immunoprecipitated 
from Lz~I-CHO  cell detergent 
lysates.  CHO  cell  transfec- 
tants (A) Mac-l,  (B) X-e-M, 
(C) M-e-X,  (D) X-a-M, (E) 
X-b-M,  (F) X-e-M-b-X, (G) 
M-b-X-a-M, (H) p150,95, (I) 
M-b-X,  (J)X-b-M-a-X,  (K) 
M-a-X,  and  (L)  M-e-X-b-M 
were  surface  labeled  with 
12~I, and immunoprecipitated 
with a negative control mAb 
(X63, lanes/); a mAb to the I 
domain  of  Mac-1 (LM2/1, 
lanes ,42, B2, F2, 12, and K2; 
a mAb to the COOH-terminal 
region of  Mac-1 (OKM1,  lanes 
D2, E2, G2, and/_,2); a mAb 
to the COOH-terminal region 
of  p150,95  (CBRpI50/4GI, 
lanes C2, H2, and J2); and a 
mAb to the CD18 /3 subunit 
(TS1/18, lanes 3) as described 
in  Materials  and  Methods. 
Material  was  boiled  in  SDS 
sample buffer with 5 %/3-mer- 
captoethanol, electrophoresed 
on a 5 % polyacrylamide gel, 
and  autoradiographed.  Mo- 
lecular  weights  of  protein 
standards are indicated to the 
left. 
duced binding weakly with an average of 5.4 +  22.1%. One 
mAb (CBRM1/32) which mapped outside the I domain to 
sites in both the NH2-terminal and divalent cation regions 
blocked binding to fibrinogen (85 %).  None of the mAbs 
against  p150,95  that were examined (Fig.  6,  and data not 
shown) inhibited adhesion to fibrinogen of neutrophils that 
were stimulated with fMLP. 
ICAM-I  + L  Cell Adhesion to Purified Mac-1.  Neutro- 
phils that are stimulated with fMLP use Mac-1 and LFA-1 
cooperatively to bind to ICAM-1 (26, 81). To identify block- 
ing mAbs more easily, we switched to an assay that examined 
Mac-1  interaction  with  ICAM-1  exclusively: ICAM-1 + L 
cell adhesion to purified Mac-1  (25). mAbs to the I domain 
inhibited binding with an average of 82.4 +  26.1%, whereas 
mAbs to the COOH-terminal region inhibited by an average 
of 24.1  +  26.8% (Fig. 6).  12 o[ the  19 I domain mAbs in- 
hibited binding by >90%  ~I  :,ea,', the. ~trongest inhibition 
by a rnAb to the COOH-terminal region was 52 %. CBRM1/ 
32 which mapped to the sites in both the NH2-terminal and 
divalent  cation  regions  inhibited  binding  strongly  (97% 
reduction). CBRM1/20, which binds directly to the divalent 
cation binding  region,  did  not block ICAM-1  binding  to 
Mac-1. 
Functional Studies with Mac-I/plSt~95 Chimeras 
To examine whether the I domain of Mac-1 was essential for 
ligand recognition, we tested the CHO cell chimeras for their 
ability to bind ICAM-1  and iC3b-E. Because control trans- 
fected or untransfected CHO cells bound constitutively to 
fibrinogen, this ligand was not tested.  Mac-1  that was ex- 
pressed in  CHO  cells was  functional as  stimulation with 
phorbol esters prompted binding to purified ICAM-1  (Fig. 
8 A). Little binding to ICAM-1  was observed in the absence 
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LPMI9c  I domain  G2a  +++ 
OKM9  I domain  GI  +++ 
LM2/1  I domain  G1  +++ 
TMG-65  I domain  G 1  +++ 
Mn4l  1 domain  GI  +++ 
14B6E.2  1 domain  M  +++ 
5A4.C5  I domain  G1  +++ 
CBRMI/1  I domain  G2b  +++ 
CBRM1/2  I domain  GI  +++ 
CBRM1/4  I dommn  Gt  +++ 
CBRM1/13  I domain  Gt  +++ 
CBRMI/21  I domain  GI  +++ 
CBRMI/22  I domain  G2a  +++ 
CBRMI/24  I dommn  G1  +++ 
CBRMI/27  ! domain  G1  +++ 
CBRMI/29  I domain  G1  +++ 
CBRMI/31  I domain  G2a  +++ 
CBRM1/33  I domain  GI  +++ 
CBRMI/34  i domain  G1  +++ 
OKMI  C-terminai  G2b  +++ 
VIMI2  C-terminal  G1  +++ 
CBRM1/9  C-tetmirial  G2a  +++ 
CBRMI/10  C-terminal  GI  +++ 
CBRMI/16  C-terminal  GI  +++ 
CBRMI/17  C-terminal  G2a  +++ 
CBRMI/18  C-tezminal  G2a  +++ 
CBRMI/23  C-terminai  G2a  +++ 
CBRM1/25  C-tea'mina]  G2a  +4-+ 
CBRM1/26  C-terminal  G2b  +++ 
CBRMI/30  C-terminal  G2b  +++ 
OKMI0ol  d  N112Jcation  G2b  +++ 
CBRMl/32  Ntl2]cation  GI  +++ 
CBRMI/20  cation  G1  +++ 
OKMl0new  ?  G2b  +++ 
CBRMI/28  ?  GI  4"+ 
p150/4G 1  p150,95  G2a 
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Figure 5. Summary of mAb reactivity as determined by immunofluorescent flow c)r  with CHO cells transfected with wild-type 
or chimeric Mac-I and p150,95 molecules. (+++)  100% of cells stained the mAb with a pattern similar to that shown in Fig. 3. (+) 
100% of ceils stained positively with the mAb but with a significantly lower fluorescence intensity. (+) The mAb stained a subpopulation 
of cells positively. (-) The mAb staining was not significantly different from the negative control (X63). 
of stimulation  (data  not  shown).  Two  chimeras  (M-a-X, 
M-b-X)  which contained the I domain of Mac-1  bound to 
ICAM-1  more weakly than anticipated.  Unexpectedly,  the 
CHO cells that expressed wild-type p150,95 also bound to 
ICAM-1.  Despite the low level of binding, it was reproduc- 
ible, inhibited by m_Abs to p150,95,  and not observed with 
control CHO cells transfected  with ICAM-1  (Fig.  8 A, and 
data not shown). Although we are uncertain of the physio- 
logic role of this p150,95-ICAM-1  interaction, p150,95 acts 
as a counter-receptor for an uncharacterized adhesion mole- 
cule on stimulated endothelial cells (86), and L cell transfec- 
tants that express ICAM-1  bind weakly to purified p150,95 
(Stacker,  S. A., and T. A.  Springer,  unpublished observa- 
tions).  Chimeras  in  which  the  I  domains  of Mac-1  and 
p150,95 were exchanged (M-e-X-b-M,  X-e-M-b-X)  showed 
no significant difference in adhesion to ICAM-1.  Although 
both wild-type Mac-1  and p150,95 transfectants  adhered to 
ICAM-1,  three chimeras (X-e-M,  X-b-M,  X-b-M-a-X)  did 
not bind to ICAM-1; these three chimeras, however, were ex- 
pressed  improperly on COS  and CHO  cells  (see  above). 
Thus, despite expressing the chimeras at relatively high lev- 
els on CHO cells, no readily interpretable  pattern of binding 
to ICAM-1  was observed. 
We tested the CHO cell transfectants  for their ability to 
bind iC3b-E. Almost all of the CHO ceils expressing wild- 
type Mac-1  rosetted with iC3b-E (Fig.  8 B).  Although the 
binding occurred in the absence of stimulation, the average 
number  of iC3b-coated  particles  per  cell  increased  after 
phorbol ester treatment  (data not shown; Diamond, M.  S., 
D.  M.  Mosser,  and  T.  A.  Springer,  unpublished observa- 
tions).  The  pattern  of  binding  of  iC3b-E  to  the  Mac- 
1/p150,95  chimeras again did not localize the binding region 
definitively (Fig. 8 B). The three chimeras (X-e-M, X-b-M, 
X-b-M-a-X)  that were not expressed properly in COS and 
CHO cells and did not bind to ICAM-1 in CHO ceils, failed 
to rosette with iC3b-E. Four chimeras that contained the I 
domain of Mac-1  (M-b-X, M-a-X, X-e-M-b-X,  and M-b-X- 
a-M) rosetted with iC3b-E, but at significantly lower levels 
than  wild-type  Mac-1  despite  similar  expression  levels. 
Wild-type p150,95 that was expressed in CHO cells did not 
bind to iC3b-E in the presence or absence of phorbol esters. 
Unexpectedly,  one chimera (M-e-X-b-M)  which contained 
the I domain of p150,95 bound iC3b consistently. In indepen- 
dent studies with transfected  COS cells, the same subset of 
chimeras rosetted with iC3b-E (data not shown). 
Discussion 
Using chimeras of Mac-1 and p150,95,  we have localized the 
epitopes for 34 mAbs to Mac-1 and correlated this with their 
The Journal of Cell Biology,  Volume 120,  1993  1038 mAb  Epitope  iC3b-E  Neutrnphil  Fibrinogen  ICAM-1 
Binding  Agllregalion  Binding  Binding 
lllhlb|tlon .%  SgM .......................................................... 
LPM19r  Idomain  94.1  .~L 5.9  81.2 •  12.3  97.7  •  t.8  t00,0 •  0.t 
OKM9  ldomain  33,6 •  9.7  &4 •  t.3  70.0 •  5.6  49.9 •  13.2 
ldomain  l&t  •  14,7  8.7 •  2.4  47.6 •  99  1t.8 •  20,4 
TMG-65  tdomain  87.1  •  14,7  35.7 +  5.9  91.8 •  &8  95.1  •  39 
Mn41  Idomain  91,5  5:10.6  30.4 +  4.7  94.0 •  0.3  93.3  +  4.0 
14B6E.2  ldomain  85.0  5:10,7  24.8  +  8:9  78.8  •  1.0  99.7 5:0.2 
5A4.C5  Idomain  97.4  •  0.7  14.3  •  5.3  71.7  •  1.0  99.9  +  0.2 
CBRMII1  Idomain  55.9  •  10.0  18.1  •  2.7  77.0 •  6,5  1O0.0 •  0A 
CBRMIr  l&~caain  63.1  •  10.5  20.7 +  5,2  76.3  •  2.4  88,7 •  2.3 
CBRMI/4  ldomaln  83,3  •  7.2  19,3  •  4,4  863  •  2,0  93,1  •  3,5 
CBRMlfI3  Idomain  36,8  •  5.0  15.3  +  2.1  45,9  •  11,3  32,3  5:13.3 
CBRMI/21  ldomain  88.6 •  8.4  21.2 •  1.6  86.8  •  2.9  99.4  •  0.4 
CBRM1/22  [domain  77,2  •  11.6  18.0 •  2,0  71.9  •  2,9  99,3  +  0,5 
CBRM1/24  Idomain  93,4  •  8,0  21.4 •  1.1  70.6  •  3.6  83.6 •  3.6 
CBRMl,,27  idomain  45.0 •  12,6  21.7 •  8.2  84.2  •  3.5  45.3  •  13,3 
CBRMIf29  ldomain  99,t  •  1,3  51.2 •  5.9  81.8 •  5.2  99.1  •  0.2 
CBRMI/3t  I~n  45,6 •  12,0  30.9 •  10.4  8t.9  •  3.3  77,5 •  13.2 
CBRM1/33  I~a-nain  94,7 •  &3  21.5  •  6.I  71,7  •  1.9  99,0 •  1.2 
CBRMI/34  Idomain  ~0~8  •  3.5  29.5 •  5.7  88.6 •  4.3  99,5 •  0.3 
OKM1  C-termlnal  38.1  •  9.3  2.2  +  1.5  -31.9 •  17,5  -41.6 +  28.3 
VIMI2  C.tcrminat  13.2 •  9.8  1.2 •  0.6  -7.3  •  9,6  4.9 •  2,7 
CBRM1/9  C.lermina]  41.4 •  2.9  0.0 •  0.7  2.8  •  7,6  3.4 •  3.1 
CBRMI/t0  C-~inal  37.2 •  2,9  2.8 •  t.0  58.0 •  5.5  423  +  4.3 
CBRMI/|6  C4~;ctinal  58.1  5:117  1,2 •  t.9  ~,.7 •  4.1  37.9 •  t5.9 
CBRMI/17  C-~ir~al  50,2 •  7.1  0.6 •  1,5  -3.4 •  4.4  21,9 +  12,4 
CBRMI/18  C-uamlna~  49.5 •  I2.8  1.3  5:2,0  3.6 +  3,2  33.8 •  16.3 
CBRM1/23  C4r  20.5  5:11,3  I.I  5:  1.|  18.0 •  3,8  12.2 5:17.5 
CBRM1/25  C.terminal  10.5 •  11.3  2.7  +  1.5  1.4  •  5.6  52.5  •  10.6 
CBRMI/26  C-terminal  9.3  •  14,5  3.2  5:1,4  29.6  5:9.5  47.8  5:18,3 
CBRMI/30  C.ten'ainal  42.5  •  9.2  3.4 •  4.2  -5.7  •  5.3  50,0  5:14.2 
OKMl0dd  NI-t2h:ation  80,9  5:21.6  ND  ND  ND 
CBRMt/32  NH2/cation  64.8  •  5.3  21.2 _•  7.3  8,*.9 •  3.8  96.8 •  1.1 
CBRMI,e20  cation  26,7  •  12,4  6.6 •  0.9  -12.9 5:9.8  5,4  •  5.6 
OKMI0new  ?  -5.7  •  11,3  9.4  5:1.2  9.6  •  11.0  25,3  +  14.8 
CBRM1/28  ?  25.7 •  IL5  0.7 5:0.2  8.8  •  2.4  2.4  •  3.4 
TSt/22  LFA-I  0.0 •  10,9  0.4 •  0.4  ND  2,7 •  %0 
plS0p4G1  pt50.95  ND  ND  -5.4 •  6.0  ND 
TSI/18  CDI8  14.1  •  3,3  75.7 •  10,2  4&5  •  6,5  91.0 •  3.5 
R15,7  CD18  46,6 •  15.1  53.0 5:2.9  89,3  •  1.8  68.3  •  11.5 
R6.5  CD54  ND  ND  ND  86.3 5:4.6 
Figure 6. Summary of the functional effects of mAbs on Mac4 in- 
teraction with tigands. The assays for the interaction with the four 
ligands  are described in Materials  and Methods. The inhibition  data 
with OKMI0o~a was  obtained from  iC3b  binding to  transfected 
COS cells instead of neutrophils. The data is expressed as the per- 
cent inhibition by each mAb and is the average of at least  three inde- 
pendent experiments. SEMs are indicated  after the :t: sign. ND, not 
determined. 
CBRMIf9,$ 
Media 
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Figure  7.  Aggregometry  profiles  of  neutrophils  activated  with 
PMA. Neutrophils were preincubated with the indicated  mAbs for 
25 rain at room temperature,  equilibrated  at 37~  and activated 
with PMA (100 ng/mi, t -  0 min). Individual representative  trac- 
ings are shown for experiments  that were performed  at least three 
times.  I/L, represents the relative  light transmission. 
Figure 8. CHO cell transfectant binding to ICAM-I (A) and iC3b-E 
(B).  (A)  Mac-l, p150,95,  Macq/p150,95  chimeras,  and  ICAM- 
1-transfected CHO  cells were detached,  resuspended  (8  x  105 
cells) in 1 ml, stimulated with PMA (100 ng/ml), and bound to im- 
munoaffinity-purified ICAM-1 adsorbed to plastic for 90 min at 
room temperature.  Unbound cells were removed by five washes 
with a transfer pipette. Bound cells were quantitated by visually 
scoring  the  number  of  cells  in  five  microscopic  fields  (40x 
magnification). Background binding to plates lacking ICAMA was 
determined for each transfectant and subtracted. The data is the av- 
erage of  three experiments and is normalized to the binding of wild- 
type Mac-1.  Bars indicate the standard error of the means.  (B) 
Transfected CHO cells were detached, reptated on tissue culture- 
treated 6-wetl plates (2 x  t05 cells/mt, 0.5 ml/welt), and adhered 
for >3 h at 37~  at 10%  CO2.  Erythrocytes (iC3b-E, 50/~1 of 2 
x  108 cells/ml) were added and incubated with transfectants for 
60  min at 37~  Nonadherent erythrocytes were  removed after 
eight washes with  a  transfer pipette and rosettes (>10  erythro- 
cytes/CHO cell, >100 cells examined) were scored by light micros- 
copy at 200x  magnification. The data is the average of three ex- 
periments. Bars indicate the standard error of the means. 
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1 molecule. This approach was used because intrepretation 
of functional assays with the Mac-1/p150,95 chimeras was 
not straightforward. We find that the 200-amino acid I do- 
main on the oc subunit of Mac-1 is a major site of ligand rec- 
ognition for iC3b,  ICAM-1, fibrinogen,  and the undefined 
counter-receptor  for neutrophil aggregation because several 
different mAbs that map to the I domain abolish binding of 
these  ligands to Mac-1. Only one mAb (CBRM1/32) that 
maps  outside  the I  domain,  to an epitope  shared  by the 
NH2-terminal and divalent cation binding regions,  blocks 
binding to iC3b, ICAM-1, and fibrinogen. None of  the mAbs 
that localize to the COOH-terminal  region strongly' blocks 
any of the adhesive interactions examined. 
In each ligand binding assay, the mAbs that abrogate bind- 
ing completely are found to map to the I domain, mAbs that 
localize to the I domain reduce adhesion 73 % for iC3b-E, 
78% for fibrinogen, 82% for ICAM-I, and 26% for neutro- 
phil  homotypic  adhesion  as  determined  by  the  Coulter 
counter assay which corresponds to 63 % inhibition by ag- 
gregometry. Two thirds of the 19 mAbs that map to the I do- 
main block Mac-1 interaction  with iC3b,  fibrinogen,  and 
ICAM-1 by >70%, and neutrophil homotypic adhesion is in- 
hibited most effectively by mAbs that map to the I domain. 
While the majority of mAbs to the I domain are strongly 
inhibitory in at least one of the assays, not all of the mAbs 
block interactions  with multiple tigands. Only five mAbs 
(LPM19c, TMG-65, Mn41, CBRM1/29, CBRM1/34) elimi- 
nate binding of all Mac-1 tigands. Many reduce binding to 
fibrinogen, ICAM-1, and iC3b but inhibit only partially neu- 
trophil homotypic adhesion. Two (OKM9 and CBRM1/27) 
that block adhesion to fibrinogen strongly, inhibit binding to 
the other three ligands weakly. Furthermore, two (CBRM1/1, 
CBRM1/2) that block adhesion to fibrinogen and ICAM-1, 
only mildly decrease binding to iC3b. The differences in pat- 
terns of mAb inhibition suggest the existence of several im- 
munoreactive  and functional  subdomains within the I do- 
main. For each ligand, some or all of  these subdomains may 
contribute  to the architecture  of the binding site. Alterna- 
tively, the I domain may contain a core sequence that facili- 
tates central recognition of all four ligands, and distinct pe- 
ripheral  sites that contribute to ligand specificity. Thus, we 
speculate that the ligand recognition sites within the I do- 
main are not identical,  but are overlapping. 
The 11 mAbs that localize to the 493-amino acid COOH- 
terminal region show little capacity to block any of  the ligand 
interactions with Mac-1. The average inhibition ranged from 
1.8% for neutrophil homotypic adhesion to 33.6% for bind- 
ing to iC3b. Thus, we suggest that the COOH-terminal re- 
gion of  Mac-1 does not contain recognition sites that mediate 
a direct interaction with any of the four ligands examined. 
Because we generated  only one mAb that maps to the 
362-amino acid region that contained the 294-amino acid 
divalent cation binding repeats and the 68 amino acids im- 
mediately  NH2-terminal to them,  little can be concluded 
about the role of this part of the molecule in ligand recogni- 
tion.  The apparent lack of immunogenicity may be attrib- 
uted,  in part,  to the 84%  amino acid identity between the 
corresponding  regions  of human  and murine  Mac-1 (16, 
70).  The  one mAb that localizes  strictly  to this  region, 
CBRM1/20, does not lessen adhesion in any of the assays by 
>30%. We cannot exclude, however, recognition sites within 
the divalent cation binding region that are not blocked by 
CBRM1/20. Indeed, a site within the divalent cation binding 
repeats of the platetet integrin ot~rd33 recognizes fibrinogen 
(19, 20). Future studies with additional mAbs to this region 
may  clarify  whether  the  strong  sequence  conservation 
among divalent cation binding modules maintains receptor 
conformation or sustains a direct interaction with ligand. 
Two mAbs to Mac-1 (OKM10old and CBRM1/32) and one 
mAb to p150,95 (SHCL3) bind to discontinuous epitopes 
that  require  the presence  of both  the  NH2-terminal and 
divalent cation binding regions of  Mac-1 or p150,95. SHCL3 
differs  from  CBRM1/32 and  OKM10o~d as  it  binds  to 
chimeras  that contain only the NH2-terminus of p150,95; 
however,  it  binds  more  strongly  when  both  the  NH2- 
terminus and divalent cation binding region of p150,95 are 
present. Importantly, these are the only mAbs that map out- 
side  the I  domain and block  ligand  interaction  strongly. 
CBRM1/32 inhibits by 70-95 % binding to iC3b, fibrinogen, 
and ICAM-1, and OKM10o~d blocks binding to iC3b (Fig. 6 
and references 4, 95) and fibrinogen (97). SHCL3 blocks 
binding of p150,95 to stimulated endothelial cells (86) but 
not to fibrinogen (69). The mapping of three mAbs to dis- 
continuous regions of the ~ chain provides immunological 
evidence for associations between the NH2-terminal and the 
divalent cation binding regions, which are separated by the 
200 amino acids of  the "inserted" or I domain. Previous elec- 
tron microscopy studies on the a~rd33 and a513~ integrins in- 
dicate  that  the  NH2-terminal  portions  of the  a  and  13 
subunits form a globular head that is linked by two stalks to 
the membrane-spanning domain (13, 41, 62). The antigenic 
relationship between the NH2-terminal and the divalent cat- 
ion binding regions suggests that the insertion in evolution 
of the I domain into a subset of integrin c~ subunits does not 
spatially separate  these  domains.  This  contrasts  with do- 
mains that are linearly arranged as "beads on a string;' such 
as  immunoglobulin  domains,  the  A  domains  of  yon 
Willebrand factor, and epidermal growth factor, fibronectin 
type IH, and short consensus repeats (ti, 21, 27, 33, 34, 42, 
54, 68, 78, 79, 90, 94). 
Despite screening on the basis of antigenic reactivity on 
peripheral blood neutrophils, the majority of new mAbs to 
Mac-1 localize to the I domain. This is unanticipated because 
the I domain composes only 18% of  the o~ subunit extracellu- 
lar domain. The tx subunits of human and murine Mac-1 are 
74% identical at the amino acid level (6,  16, 70),  with the 
divalent cation binding region having the greatest identity 
(84%)  and  the  COOH-terminal  region  the  least  identity 
(74%) among extracellular domains. It is unclear why the I 
domain is immunodominant; it is intermediate in homology 
(81%  identity),  similar  in  size  to the NH2-terminal and 
divalent cation binding regions, and smaller than the COOH- 
terminal region. 
Although the studies with mAbs show that the I domain 
is an important ligand recognition site, no discernible pattern 
is observed when the Mac-1 and p150,95 chimeras are tested 
in functional  assays. Attempts to generate  chimeras  with 
Mac-1 and LFA-1 which have less amino acid identity and 
ligand overlap were unsuccessful as these molecules  were 
not expressed on the surface of COS cells (48). Several fac- 
tors may contribute to the failure to locate directly the bind- 
ing sites for iC3b and ICAM-1 with the chimeric molecules. 
Increasing evidence suggests that Mac-1 and p150,95 bind a 
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and iC3b (57, 61, 72). However, in our experiments, iC3b-E 
do not rosette with transfected CHO cells expressing p150,95 
(Fig. 8 B). Possibly, in transfected cells, p150,95 lacks the 
proper conformation to bind iC3b. On leukocytes, to recog- 
nize ligands, Mac-1 and LFA-1 convert from a low avidity to 
high avidity state (12, 28, 51, 93). Conformational changes 
appear  to be  transmitted by signals from within the cell 
through the cytoplasmic domains of integrin subunits (38, 
39,  63).  Conformational changes that enhance or  inhibit 
ligand binding may also arise when chimeric a  subunits are 
constructed or when nonnative otfl subunit associations oc- 
cur. In favor of this, a hybrid p150,95  molecule comprised 
of a human ax subunit and chicken t2 subunit expressed in 
COS cells rosettes strongly with iC3b-E although the wild- 
type human c: human 82 molecule does not (Bilsland, C., 
and T. A. Springer, unpublished observations). Our experi- 
ments also suggest that at least in vitro, p150,95 binds weakly 
to ICAM-1 (Fig. 8 A). The I domain ofp150,95 in the context 
of a wild-type p150,95  frame binds to ICAM-1 poorly, but 
in the context of a Mac-1 frame (M-e-X-b-M)  in which other 
ligand binding sites may be present or the conformation is 
altered, the binding to ICAM-1  is enhanced. 
The interpretation of the functional assays also is compli- 
cated by the improper expression or association with the/3 
subunit by three of the chimeric a  subunits (X-e-M, X-b-M, 
X-b-M-a-X) in CHO cells. In immunoprecipitates with the 
subunit mAb (TS1/18), these three chimeras are weak or 
lacking, although the/3 subunit is still associated with the a 
subunit as it coprecipitates with the a  subunit-specific mAbs. 
TS1/18 has previously been shown to precipitate native c~/3 
complexes, but not the unassociated/~ subunit (85). In the 
present study, TS1/18 does not recognize normally the a/~ 
complex of X-e-M, X-b-M, and X-b-M-a-X after detergent 
solubilization, although it does react with these chimeras on 
intact  CHO  cells.  In  addition,  the  amount of fl  subunit 
precipitated by anti-c~  subunit mAbs is  reduced in these 
three chimeras relative to the other c~ subunits. Solubiliza- 
tion may dissociate an inherently weak interaction between 
the X-e-M, X-b-M, and X-b-M-a-X chimeric ot subunits and 
the/3 subunit. In contrast, the parental ot subunits, o~  ~ and 
o~  x, and other chimeric o~ subunits associate stably with the 
subunit. The common feature of these unstable c~ subunit 
chimeras  is  the  presence  of the  NH2-terminal  region  of 
p150,95  and the divalent cation binding region of Mac-1. 
These findings suggest that these two regions interact, and 
that in the above combinations there are noncomplementary 
amino acid residues that prevent proper folding of the chi- 
meric a  subunit and association with the fl subunit. In light 
of this, it is not surprising that X-e-M, X-b-M, and X-b-M-a-X 
do not bind to iC3b or ICAM-1 when expressed in CHO or 
COS cells. Two other chimeras (M-a-X and M-b-X), which 
contain the I domain of Mac-1 and bind to ICAM-1 and iC3b 
poorly, show evidence of subtle structural anomalies based 
on changes in antigenic reactivity. M-a-X and M-b-X show 
a reduction or loss of binding of two mAbs that map to the 
I  domain:  CBRM1/2  (Fig.  5)  and  CBRM1/5  (24).  It  is 
noteworthy that CBRM1/5  recognizes a  subpopulation of 
functionally active  Mac-1  molecules  on  neutrophils  and 
monocytes (23), and is expressed on other chimeras (X-e-M- 
b-X, M-b-X-a-M) that contain the I domain of Mac-1 and 
bind ligand (data not shown). The molecular packing of the 
ot subunits of Moa-X and M-b-X may be disrupted sufficiently 
so that these chimeras cannot attain a conformation that sus- 
tains ligand binding. 
In summary, the studies presented here suggest that the I 
domain on Mac-I is a major recognition site for both cellular 
and soluble ligands. Previously, because of its homology to 
ligand binding regions in yon Willebrand factor, cartilage 
matrix protein, and complement proteins, the evolutionarily 
inserted I  domain has been speculated to be important in 
ligand recognition (49, 70). This is the first study to demon- 
strate a role for the I domain on integrin ot subunits. Future 
amino acid substitution studies are required to delineate the 
amino acids in the I domain of Mac-1 that contact individual 
ligands. It will be interesting to examine whether the I do- 
main is similarly important for the other integrins that con- 
tain it, LFA-I, p150,95,  VLA-1, and VLA-2. 
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